**Table 2:** Study population, interventions, outcomes and follow up

|  |  |  |  |
| --- | --- | --- | --- |
| Study ID | Stent | Operation  | Follow up and results (MIDCAB/CABG vs DES) |
| Benedetto 2014 | DES | MIDCAB, LIMA | 2232 days: Deaths 13/303 vs 31/303, HR 2.19(1.15-4.17). TVR 10 vs 31, HR 3.1(1.35-4.21). Death/TVR HR 2.14(1.41-3.24). |
| Blazek 2015 | DES  | MIDCAB, LIMA | 7.3 years: Composite 8/65vs 14/64, RR 1.47(0.82-2.62). Death 11 vs 9, RR 0.91(0.58-1.39). MI 6 vs 4, RR 0.83(0.48-1.41). TVR 1 vs 13, RR 7.79(1.17-51.87). |
| Buszman 2011 | DES | MIDCAB | 5 years: MACCE 71/276 vs 62/178. Death 12vs 12. MI 12vs 9. Revascularization 38vs 67. |
| Glineur 2009 | DES | MIDCAB | 2 years: MACCE 23/175 vs 65/175, HR 0.33(0.19-0.55). Death7 vs 7, HR 0.76(0.25-2.30). MI2 vs 5, HR 0.25(0.03-2.36). Stroke 4 vs 9, HR 0.28(0.05-1.46). TVR5 vs 26, HR 0.19(0.07-0.49). |
| Hannan 2014 | DES | - | 3 years: Composite 56/715 vs 46/715, aHR 1.15(0.76-1.73). Death 39 vs 34, aHR 1.14(0.70-1.85). Revascularization42 vs 77, aHR 0.54(0.36-0.81). |
| Hong 2005 | DES | MIDCAB , LIMA | 6 months: Death 2/68 vs 0/116. MI 2vs 2, RR 0.73(0.27-1.99). TVR 1vs 3, RR 1.49(0.27-8.22). |
| Jones 2011 | DES | LIMA graft | 4 years: MACE 15/122 vs 89/752. Death 10 vs 32. TVR 3 vs 44. |
| Patsa 2010 | DES | LIMA graft | 26 months: Death 2/110 vs 5/302. MI 1 vs 2. Target lesion revascularization 0 vs 7. |
| Thiele 2009 | DES | MIDCAB, LIMA | 12 months: MACE 5/65vs 5/65. MI 5 vs 1. TVR 0 vs 4. |
| Toutouzas 2007 | DES | CABG, LIMA | 18 months: MACE 3/110 vs 4/147. Death 2 vs 3. MI 1 vs 0. TVR 0 vs 3. |
| Ungureanu 2013 | DES | MIDCAB | 2 years: TVR 4/154 vs 5/50. Stroke2 vs 0.  |

DES=drug eluting stent, MIDCAB=minimally invasive direct coronary artery bypass, LIMA=left internal mammary artery, CABG=coronary artery bypass graft; TVR=target vessel revascularization, MI=myocardial infarction, MACE=major adverse cardiovascular events, MACCE=major adverse cardiovascular or cerebrovascular event, RR=relative risk, HR=hazard ratio.